Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer

A Small Molecule Inhibitor to Plasminogen Activator Inhibitor 1 Inhibits Macrophage Migration

(2013) Atsuhiko Ichimura et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Plasminogen Activator Inhibitor-1 Antagonist TM5441 Attenuates N ω -Nitro- l -Arginine Methyl Ester–Induced Hypertension and Vascular Senescence

(2013) Amanda E. Boe et al.   CIRCULATION

The plasminogen activation system: new targets in lung inflammation and remodeling

(2013) Michael Schuliga et al.   CURRENT OPINION IN PHARMACOLOGY

Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates with Worsened Prognosis

(2013) Yoriko Yamashita et al.   PLoS One

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Protumorigenic Activity of Plasminogen Activator Inhibitor-1 Through an Antiapoptotic Function

(2012) Hua Fang et al.   JNCI-Journal of the National Cancer Institute

Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient

(2011) Sohei Yamamoto et al.   MODERN PATHOLOGY

Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer

(2011) C Alberti et al.   ONCOGENE

A Novel Inhibitor of Plasminogen Activator Inhibitor-1 Provides Antithrombotic Benefits Devoid of Bleeding Effect in Nonhuman Primates

(2010) Yuko Izuhara et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy

(2010) Dragomir P Zubac et al.   BMC Urology

When ‘never-events’ occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes

(2009) Linda R. Duska et al.   GYNECOLOGIC ONCOLOGY

Cancer and thrombosis in women – molecular mechanisms

(2009) Frederick R. Rickles   THROMBOSIS RESEARCH

A comparison among HER2,TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer

(2008) Birgitte Vrou Offersen et al.   ACTA ONCOLOGICA

Plasminogen Activator Inhibitor-1 Protects Endothelial Cells from FasL-Mediated Apoptosis

(2008) Khalid Bajou et al.   CANCER CELL

Evolving role of uPA/uPAR system in human cancers

(2008) Kathleen Dass et al.   CANCER TREATMENT REVIEWS

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

(2008) R. W. Tothill et al.   CLINICAL CANCER RESEARCH